Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $35.7 million.

  • Amicus Therapeutics' Cash from Operations rose 25523.92% to $35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 14893.46%. This contributed to the annual value of -$33.9 million for FY2024, which is 5094.73% up from last year.
  • Per Amicus Therapeutics' latest filing, its Cash from Operations stood at $35.7 million for Q3 2025, which was up 25523.92% from -$26.5 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Cash from Operations registered a high of $35.7 million during Q3 2025, and its lowest value of -$80.8 million during Q4 2022.
  • Over the past 5 years, Amicus Therapeutics' median Cash from Operations value was -$23.0 million (recorded in 2024), while the average stood at -$24.0 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Cash from Operations plummeted by 22983.83% in 2023, and later soared by 25523.92% in 2025.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Cash from Operations stood at -$70.5 million in 2021, then dropped by 14.55% to -$80.8 million in 2022, then soared by 104.28% to $3.5 million in 2023, then tumbled by 213.24% to -$3.9 million in 2024, then soared by 1010.62% to $35.7 million in 2025.
  • Its Cash from Operations was $35.7 million in Q3 2025, compared to -$26.5 million in Q2 2025 and $7.8 million in Q1 2025.